An independent team at the University of Minnesota is conducting a comprehensive review of evidence supporting meningococcal and pneumococcal vaccines in children and young adults, seeking to inform policy amidst ongoing legal and political debates and rising disease cases.
An independent team at the University of Minnesota is taking a fresh look at the evidence behind meningococcal and pneumococcal vaccination in children and young adults, as debate continues over how those shots are recommended in the United States. The Vaccine Integrity Project, housed at the university’s Centre for Infectious Disease Research and Policy, said it will systematically review the science supporting the vaccines, with executive director Michael Osterholm arguing that parents and clinicians need confidence that policy is based on a broad and transparent appraisal of the evidence.
The review will cover every meningococcal vaccine licensed in the US, including MenACWY, MenB and newer MenABCWY products, as well as pneumococcal vaccines for children. The project has already produced similar independent reviews on influenza, Covid-19, RSV, the hepatitis B birth dose, HPV and Tdap during pregnancy. It is funded by an unrestricted gift from the Alumbra foundation, established by philanthropist Christy Walton, and it has no regulatory authority of its own.
The timing matters because the federal childhood schedule has already been pulled into legal and political dispute. In January, the Department of Health and Human Services issued a revised schedule that moved meningococcal vaccines into a higher-risk category, while keeping pneumococcal vaccination on the routine list for all children. But a federal judge in Massachusetts later issued a preliminary injunction in American Academy of Pediatrics v. Kennedy that put those changes on hold, along with related votes by a reconstituted advisory committee and the appointments of its members. For now, the earlier guidance remains in place, although the case is still being litigated.
That uncertainty comes as meningococcal disease, though rare, has risen in the US since 2021, largely because of serogroup Y, which is preventable by vaccine. The Centers for Disease Control and Prevention says the infection can become life-threatening quickly and can lead to meningitis or bloodstream infection. Pneumococcal disease, which can also cause pneumonia, meningitis and bloodstream infections, remains a particular threat to young children. The CDC recommends pneumococcal vaccination for all children under five, and meningococcal vaccination for adolescents and young adults, especially those in higher-risk settings such as close-contact environments or during outbreaks.
For families, the practical questions are immediate. Vaccine category affects how private insurance covers the shot, and shared clinical decision-making can leave some parents unsure whether a vaccine is routinely expected or should be discussed case by case. Health specialists say the prudent approach is not to wait for the review to finish, but to ask a child’s clinician whether a dose is due, whether it is covered, and whether the child qualifies for the federal Vaccines for Children programme.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
